Haloperidol Injection
Generic name: Pronounced as (ha loe per' i dole)
Medical Content Reviewed By HelloPharmacist Staff
Last Revised - 07/15/2017
On this page
- Why is this medication prescribed?
- How should this medicine be used?
- Other uses for this medicine
- What special precautions should I follow?
- What special dietary instructions should I follow?
- What should I do if I forget a dose?
- What side effects can this medication cause?
- What should I do in case of OVERDOSE?
- What OTHER INFORMATION should I know?
- Drug interactions
IMPORTANT WARNING
Studies have shown that older adults with dementia (a brain disorder that affects the ability to remember, think clearly, communicate, and perform daily activities and that may cause changes in mood and personality) who take antipsychotics (medications for mental illness) such as haloperidol have an increased chance of death during treatment.
Haloperidol injection and haloperidol extended-release injection are not approved by the Food and Drug Administration (FDA) for the treatment of behavior disorders in older adults with dementia. Talk to the doctor who prescribed this medication if you, a family member, or someone you care for has dementia and is being treated with haloperidol injection or haloperidol extended-release injection. For more information visit the FDA website: http://www.fda.gov/Drugs
Talk to your doctor about the risk(s) of receiving haloperidol injection or haloperidol extended-release injection.
Why is this medication prescribed?
Haloperidol injection and haloperidol extended-release injection are used to treat schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions). Haloperidol injection is also used to control motor tics (uncontrollable need to repeat certain body movements) and verbal tics (uncontrollable need to repeat sounds or words) in people who have Tourette's disorder (condition characterized by motor or verbal tics). Haloperidol is in a class of medications called conventional antipsychotics. It works by decreasing abnormal excitement in the brain.
How should this medicine be used?
Haloperidol injection comes as a solution to be injected into a muscle by a healthcare provider. Haloperidol injection is usually given as needed for agitation, motor tics, or verbal tics. If you still have symptoms after you receive your first dose, you may be given one or more additional doses. Haloperidol extended-release injection comes as a solution to be injected into a muscle by a healthcare provider. Haloperidol extended-release injection is usually given once every 4 weeks.
Haloperidol injection and haloperidol extended-release injection may help control your symptoms but will not cure your condition. Continue to keep appointments to receive haloperidol even if you feel well. Talk to your doctor if you do not feel like you are getting better during your treatment with haloperidol injection.
Ask your pharmacist or doctor for a copy of the manufacturer's information for the patient.
Other uses for this medicine
This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.
What special precautions should I follow?
Before receiving haloperidol injection or haloperidol extended-release injection,
-
tell your doctor and pharmacist if you are allergic to haloperidol, any other medications, or any of the ingredients in haloperidol injection or haloperidol extended-release injection. Ask your pharmacist for a list of the ingredients.
-
tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: alprazolam (Xanax); amiodarone (Cordarone, Nexterone, Pacerone); anticoagulants (blood thinners); antifungals medications such as itraconazole (Onmel, Sporanox) and ketoconazole (Nizoral); antihistamines (in cough and cold medications); medications for anxiety, depression, irritable bowel disease, mental illness, motion sickness, Parkinson's disease, seizures, ulcers, or urinary problems; buspirone; carbamazepine (Carbatrol, Tegretol, Teril, others); chlorpromazine; disopyramide (Norpace); diuretics ('water pills'); epinephrine (Adrenalin, Epipen, Twinject, others); erythromycin (E.E.S., E-Mycin, Erythrocin); fluoxetine (Prozac, Sarafem, Selfemra); fluvoxamine (Luvox); lithium (Lithobid); moxifloxacin (Avelox); narcotic medications for pain; nefazodone; paroxetine (Brisdelle, Paxil, Pexeva); promethazine (Promethegan); quinidine (in Nuedexta); rifampin (Rifadin, Rimactane, in Rifamate, in Rifater); sedatives; sertraline (Zoloft); sleeping pills; tranquilizers; and venlafaxine (Effexor XR). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with haloperidol, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
-
tell your doctor if you have Parkinson's disease (PD; a disorder of the nervous system that causes difficulties with movement, muscle control, and balance). Your doctor will probably tell you not to receive haloperidol injection.
-
tell your doctor if you have a low number of white blood cells. Also tell your doctor if you have or have ever had QT prolongation (an irregular heart rhythm that can lead to fainting, loss of consciousness, seizures, or sudden death); bipolar disorder (condition that causes episodes of depression, episodes of mania, and other abnormal moods); trouble keeping your balance; an abnormal electroencephalogram (EEG; a test that records electrical activity in the brain); seizures; an irregular heartbeat; low levels of potassium or magnesium in your blood; or heart or thyroid disease.
-
tell your doctor if you are pregnant, especially if you are in the last few months of your pregnancy, or if you plan to become pregnant or are breastfeeding. If you become pregnant while receiving haloperidol, call your doctor. Haloperidol may cause problems in newborns following delivery if it is given during the last months of pregnancy.
-
if you are having surgery, including dental surgery, tell the doctor or dentist that you are receiving haloperidol injection.
-
you should know that receiving haloperidol injection or haloperidol extended-release injection may make you drowsy and may affect your ability to think clearly, make decisions, and react quickly. Do not drive a car or operate machinery after you receive haloperidol injection or haloperidol extended-release injection until you know how this medication affects you.
-
you should know that alcohol can add to the drowsiness caused by this medication. Do not drink alcohol during your treatment with haloperidol.
-
you should know that haloperidol injection may cause dizziness, lightheadedness, and fainting when you get up too quickly from a lying position. To avoid this problem, get out of bed slowly, resting your feet on the floor for a few minutes before standing up.
What special dietary instructions should I follow?
Unless your doctor tells you otherwise, continue your normal diet.
What should I do if I forget a dose?
If you forget to keep an appointment to receive haloperidol extended-release injection, call your doctor to schedule another appointment as soon as possible.
What side effects can this medication cause?
-
Haloperidol injection or haloperidol extended-release injection may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:
-
mood changes
-
difficulty falling asleep or staying asleep
-
restlessness
-
anxiety
-
agitation
-
dizziness, feeling unsteady, or having trouble keeping your balance
-
headache
-
dry mouth
-
increased saliva
-
blurred vision
-
loss of appetite
-
constipation
-
diarrhea
-
heartburn
-
nausea
-
vomiting
-
breast enlargement or pain
-
breast milk production
-
missed menstrual periods
-
decreased sexual ability in men
-
increased sexual desire
-
difficulty urinating
-
-
Some side effects can be serious. If you experience any of these symptoms, call your doctor immediately or get emergency medical treatment:
-
fever
-
muscle stiffness
-
falling
-
confusion
-
fast or irregular heartbeat
-
sweating
-
decreased thirst
-
involuntary movements of tongue, face, mouth or jaw
-
uncontrollable eye movements
-
unusual, slowed, or uncontrollable movements of any part of the body
-
tightness in the throat
-
fine, worm-like tongue movements
-
neck cramps
-
difficulty breathing or swallowing
-
tongue that sticks out of the mouth
-
uncontrollable, rhythmic face, mouth, or jaw movements
-
difficulty walking
-
difficulty talking
-
seizures
-
seeing things or hearing voices that do not exist
-
yellowing of the skin or eyes
-
erection that lasts for hours
-
-
Haloperidol injection or haloperidol extended-release injection may cause other side effects. Call your doctor if you have any unusual problems while receiving this medication.
-
If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).
What should I do in case of OVERDOSE?
In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.
Symptoms of overdose may include the following:
-
unusual, slowed, or uncontrollable movements of any part of the body
-
uncontrollable shaking of a part of the body
-
stiff or weak muscles
-
sedation
What OTHER INFORMATION should I know?
Keep all appointments with your doctor and the laboratory. Your doctor may order certain lab tests to check your body's response to haloperidol injection or haloperidol extended-release injection.
Ask your pharmacist any questions you have about haloperidol injection or haloperidol extended-release injection.
It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.
Drug interactions
Drug | Interaction |
---|---|
Moxifloxacin | Moxifloxacin The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Haloperidol. |
Repaglinide | Repaglinide The serum concentration of Repaglinide can be increased when it is combined with Haloperidol. |
Montelukast | Montelukast The serum concentration of Haloperidol can be increased when it is combined with Montelukast. |
Insulin Glargine (rDNA origin) Injection | Insulin Glargine (rDNA origin) Injection The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Haloperidol. |
Leflunomide | Leflunomide The serum concentration of Haloperidol can be decreased when it is combined with Leflunomide. |
Delavirdine | Delavirdine The serum concentration of Haloperidol can be increased when it is combined with Delavirdine. |
Nevirapine | Nevirapine The serum concentration of Haloperidol can be increased when it is combined with Nevirapine. |
Atorvastatin | Atorvastatin The metabolism of Atorvastatin can be decreased when combined with Haloperidol. |
Dolasetron | Dolasetron The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Dolasetron. |
Aminophylline | Aminophylline The serum concentration of Aminophylline can be increased when it is combined with Haloperidol. |
Anagrelide | Anagrelide The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Anagrelide. |
Candesartan | Candesartan The metabolism of Haloperidol can be decreased when combined with Candesartan. |
Cilostazol | Cilostazol The metabolism of Cilostazol can be decreased when combined with Haloperidol. |
Clopidogrel | Clopidogrel The serum concentration of Haloperidol can be increased when it is combined with Clopidogrel. |
Diphenoxylate | Diphenoxylate The risk or severity of CNS depression can be increased when Haloperidol is combined with Diphenoxylate. |
Erythromycin and Sulfisoxazole | Erythromycin and Sulfisoxazole The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Haloperidol. |
Estrogen and Progestin (Oral Contraceptives) | Estrogen and Progestin (Oral Contraceptives) The serum concentration of Haloperidol can be increased when it is combined with Conjugated estrogens. |
Fenofibrate | Fenofibrate The serum concentration of Haloperidol can be increased when it is combined with Fenofibrate. |
Guanfacine | Guanfacine The risk or severity of CNS depression can be increased when Haloperidol is combined with Guanfacine. |
Magnesium Hydroxide | Magnesium Hydroxide Haloperidol may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level. |
Methylergonovine | Methylergonovine The serum concentration of Haloperidol can be increased when it is combined with Methylergometrine. |
Miglitol | Miglitol The therapeutic efficacy of Miglitol can be decreased when used in combination with Haloperidol. |
Mycophenolate | Mycophenolate Haloperidol may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level. |
Naratriptan | Naratriptan The risk or severity of CNS depression can be increased when Naratriptan is combined with Haloperidol. |
Olsalazine | Olsalazine The therapeutic efficacy of Haloperidol can be increased when used in combination with Olsalazine. |
Paregoric | Paregoric The risk or severity of CNS depression can be increased when Morphine is combined with Haloperidol. |
Penbutolol | Penbutolol The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Acebutolol. |
Pentazocine | Pentazocine The risk or severity of CNS depression can be increased when Haloperidol is combined with Pentazocine. |
Potassium | Potassium Potassium may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy. |
Prednisone | Prednisone The serum concentration of Haloperidol can be increased when it is combined with Prednisone. |
Ranitidine | Ranitidine The serum concentration of Ranitidine can be increased when it is combined with Haloperidol. |
Reserpine | Reserpine The risk or severity of CNS depression can be increased when Reserpine is combined with Haloperidol. |
Rizatriptan | Rizatriptan The risk or severity of CNS depression can be increased when Haloperidol is combined with Rizatriptan. |
Sumatriptan | Sumatriptan The risk or severity of CNS depression can be increased when Haloperidol is combined with Sumatriptan. |
Tacrolimus | Tacrolimus The serum concentration of Tacrolimus can be increased when it is combined with Haloperidol. |
Tizanidine | Tizanidine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Tizanidine. |
Triamcinolone | Triamcinolone The serum concentration of Haloperidol can be increased when it is combined with Triamcinolone. |
Zolmitriptan | Zolmitriptan The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Haloperidol. |
Ampicillin Injection | Ampicillin Injection Ampicillin may decrease the excretion rate of Haloperidol which could result in a higher serum level. |
Doxycycline Injection | Doxycycline Injection The serum concentration of Haloperidol can be increased when it is combined with Doxycycline. |
Famotidine Injection | Famotidine Injection The risk or severity of QTc prolongation can be increased when Famotidine is combined with Haloperidol. |
Fluconazole Injection | Fluconazole Injection The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Haloperidol. |
Foscarnet Injection | Foscarnet Injection The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Haloperidol. |
Hydromorphone Injection | Hydromorphone Injection The risk or severity of CNS depression can be increased when Hydromorphone is combined with Haloperidol. |
Interferon Beta-1b Injection | Interferon Beta-1b Injection The metabolism of Haloperidol can be decreased when combined with Interferon beta-1b. |
Interferon Gamma-1b Injection | Interferon Gamma-1b Injection The metabolism of Haloperidol can be decreased when combined with Interferon gamma-1b. |
Levofloxacin Injection | Levofloxacin Injection The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Haloperidol. |
Meperidine Injection | Meperidine Injection The risk or severity of CNS depression can be increased when Haloperidol is combined with Meperidine. |
Methylprednisolone Injection | Methylprednisolone Injection The serum concentration of Haloperidol can be increased when it is combined with Methylprednisolone. |
Metoclopramide Injection | Metoclopramide Injection The risk or severity of adverse effects can be increased when Metoclopramide is combined with Haloperidol. |
Metronidazole Injection | Metronidazole Injection The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Haloperidol. |
Morphine Injection | Morphine Injection The risk or severity of CNS depression can be increased when Morphine is combined with Haloperidol. |
Pamidronate Injection | Pamidronate Injection Pamidronic acid may decrease the excretion rate of Haloperidol which could result in a higher serum level. |
Vancomycin Injection | Vancomycin Injection Haloperidol may decrease the excretion rate of Vancomycin which could result in a higher serum level. |
Zidovudine Injection | Zidovudine Injection The serum concentration of Haloperidol can be increased when it is combined with Zidovudine. |
Altretamine | Altretamine The therapeutic efficacy of Amphetamine can be decreased when used in combination with Haloperidol. |
Cefuroxime | Cefuroxime Cefuroxime may decrease the excretion rate of Haloperidol which could result in a higher serum level. |
Cyclosporine | Cyclosporine The serum concentration of Cyclosporine can be increased when it is combined with Haloperidol. |
Ondansetron | Ondansetron The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Ondansetron. |
Granisetron | Granisetron The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Granisetron. |
Torsemide | Torsemide The metabolism of Haloperidol can be decreased when combined with Torasemide. |
Olanzapine | Olanzapine The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Haloperidol. |
Alosetron | Alosetron The risk or severity of CNS depression can be increased when Alosetron is combined with Haloperidol. |
Dofetilide | Dofetilide The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Dofetilide. |
Entacapone | Entacapone The risk or severity of CNS depression can be increased when Entacapone is combined with Haloperidol. |
Hydroxychloroquine | Hydroxychloroquine The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Haloperidol. |
Meloxicam | Meloxicam The serum concentration of Haloperidol can be increased when it is combined with Meloxicam. |
Oxcarbazepine | Oxcarbazepine The risk or severity of CNS depression can be increased when Oxcarbazepine is combined with Haloperidol. |
Pantoprazole | Pantoprazole The serum concentration of Haloperidol can be increased when it is combined with Pantoprazole. |
Temozolomide | Temozolomide Haloperidol may decrease the excretion rate of Temozolomide which could result in a higher serum level. |
Zaleplon | Zaleplon The risk or severity of CNS depression can be increased when Haloperidol is combined with Zaleplon. |
Anakinra | Anakinra The metabolism of Haloperidol can be increased when combined with Anakinra. |
Desloratadine | Desloratadine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Desloratadine. |
Linezolid | Linezolid The risk or severity of CNS depression can be increased when Linezolid is combined with Haloperidol. |
Trimipramine | Trimipramine The serum concentration of Trimipramine can be increased when it is combined with Haloperidol. |
Etanercept Injection | Etanercept Injection The metabolism of Haloperidol can be increased when combined with Etanercept. |
Glycopyrrolate | Glycopyrrolate Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium. |
Modafinil | Modafinil The metabolism of Haloperidol can be increased when combined with Armodafinil. |
Perindopril | Perindopril Haloperidol may decrease the excretion rate of Perindopril which could result in a higher serum level. |
Tenofovir | Tenofovir The serum concentration of Haloperidol can be increased when it is combined with Tenofovir. |
Choline Magnesium Trisalicylate | Choline Magnesium Trisalicylate The therapeutic efficacy of Haloperidol can be increased when used in combination with Choline magnesium trisalicylate. |
Sirolimus | Sirolimus The serum concentration of Sirolimus can be increased when it is combined with Haloperidol. |
Dutasteride | Dutasteride The metabolism of Dutasteride can be decreased when combined with Haloperidol. |
Epinephrine Injection | Epinephrine Injection The serum concentration of Haloperidol can be increased when it is combined with Epinephrine. |
Eplerenone | Eplerenone The metabolism of Eplerenone can be decreased when combined with Haloperidol. |
Escitalopram | Escitalopram The serum concentration of Escitalopram can be increased when it is combined with Haloperidol. |
Zonisamide | Zonisamide The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Zonisamide. |
Adalimumab Injection | Adalimumab Injection The metabolism of Haloperidol can be increased when combined with Adalimumab. |
Aripiprazole | Aripiprazole The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Aripiprazole. |
Atomoxetine | Atomoxetine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Atomoxetine. |
Dexmethylphenidate | Dexmethylphenidate The risk or severity of CNS depression can be increased when Haloperidol is combined with Dexmethylphenidate. |
Atazanavir | Atazanavir The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Haloperidol. |
Almotriptan | Almotriptan The risk or severity of CNS depression can be increased when Almotriptan is combined with Haloperidol. |
Eletriptan | Eletriptan The risk or severity of CNS depression can be increased when Haloperidol is combined with Eletriptan. |
Mefloquine | Mefloquine The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Haloperidol. |
Rosuvastatin | Rosuvastatin The serum concentration of Rosuvastatin can be increased when it is combined with Haloperidol. |
Vardenafil | Vardenafil The metabolism of Vardenafil can be decreased when combined with Haloperidol. |
Alfuzosin | Alfuzosin The metabolism of Alfuzosin can be decreased when combined with Haloperidol. |
Aprepitant | Aprepitant The serum concentration of Haloperidol can be increased when it is combined with Aprepitant. |
Emtricitabine | Emtricitabine Haloperidol may decrease the excretion rate of Emtricitabine which could result in a higher serum level. |
Interferon Beta-1a Subcutaneous Injection | Interferon Beta-1a Subcutaneous Injection The metabolism of Haloperidol can be decreased when combined with Interferon beta-1a. |
Memantine | Memantine The risk or severity of adverse effects can be increased when Haloperidol is combined with Memantine. |
Tegaserod | Tegaserod The serum concentration of Haloperidol can be increased when it is combined with Tegaserod. |
Tadalafil | Tadalafil The serum concentration of Tadalafil can be increased when it is combined with Haloperidol. |
Fosamprenavir | Fosamprenavir The serum concentration of Haloperidol can be increased when it is combined with Fosamprenavir. |
Frovatriptan | Frovatriptan The risk or severity of CNS depression can be increased when Haloperidol is combined with Frovatriptan. |
Gemifloxacin | Gemifloxacin The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Gemifloxacin. |
Progesterone | Progesterone The serum concentration of Haloperidol can be increased when it is combined with Progesterone. |
Apomorphine Injection | Apomorphine Injection The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Haloperidol. |
Infliximab Injection | Infliximab Injection The metabolism of Haloperidol can be increased when combined with Infliximab. |
Oxandrolone | Oxandrolone The metabolism of Haloperidol can be decreased when combined with Oxandrolone. |
Protriptyline | Protriptyline The serum concentration of Haloperidol can be increased when it is combined with Protriptyline. |
Rifaximin | Rifaximin The serum concentration of Haloperidol can be increased when it is combined with Rifaximin. |
Duloxetine | Duloxetine The risk or severity of CNS depression can be increased when Duloxetine is combined with Haloperidol. |
Norethindrone | Norethindrone The serum concentration of Norethisterone can be increased when it is combined with Haloperidol. |
Tinidazole | Tinidazole The serum concentration of Tinidazole can be increased when it is combined with Haloperidol. |
Trospium | Trospium The serum concentration of Trospium can be increased when it is combined with Haloperidol. |
Bosentan | Bosentan The serum concentration of Haloperidol can be increased when it is combined with Bosentan. |
Cefditoren | Cefditoren Haloperidol may decrease the excretion rate of Cefdinir which could result in a higher serum level. |
Cinacalcet | Cinacalcet The serum concentration of Haloperidol can be increased when it is combined with Cinacalcet. |
Cyanocobalamin Injection | Cyanocobalamin Injection Hydroxocobalamin may decrease the excretion rate of Haloperidol which could result in a higher serum level. |
Erlotinib | Erlotinib The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Erlotinib. |
Eszopiclone | Eszopiclone The risk or severity of CNS depression can be increased when Haloperidol is combined with Eszopiclone. |
Ganciclovir | Ganciclovir Haloperidol may decrease the excretion rate of Ganciclovir which could result in a higher serum level. |
Insulin Aspart (rDNA Origin) Injection | Insulin Aspart (rDNA Origin) Injection The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Haloperidol. |
Ribavirin | Ribavirin Haloperidol may decrease the excretion rate of Ribavirin which could result in a higher serum level. |
Solifenacin | Solifenacin The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Haloperidol. |
Valganciclovir | Valganciclovir Haloperidol may decrease the excretion rate of Valganciclovir which could result in a higher serum level. |
Voriconazole | Voriconazole The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Haloperidol. |
Adefovir | Adefovir Adefovir may decrease the excretion rate of Haloperidol which could result in a higher serum level. |
Dextroamphetamine | Dextroamphetamine The therapeutic efficacy of Amphetamine can be decreased when used in combination with Haloperidol. |
Entecavir | Entecavir The metabolism of Haloperidol can be decreased when combined with Entecavir. |
Peginterferon Alfa-2a Injection | Peginterferon Alfa-2a Injection The metabolism of Haloperidol can be decreased when combined with Peginterferon alfa-2a. |
Peginterferon Alfa-2b (PEG-Intron) | Peginterferon Alfa-2b (PEG-Intron) The serum concentration of Haloperidol can be increased when it is combined with Peginterferon alfa-2b. |
Pramlintide Injection | Pramlintide Injection The therapeutic efficacy of Pramlintide can be decreased when used in combination with Haloperidol. |
Sodium Oxybate | Sodium Oxybate The risk or severity of CNS depression can be increased when Sodium oxybate is combined with Haloperidol. |
Exenatide Injection | Exenatide Injection The therapeutic efficacy of Exenatide can be decreased when used in combination with Haloperidol. |
Ibandronate | Ibandronate The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Haloperidol. |
Isocarboxazid | Isocarboxazid The risk or severity of CNS depression can be increased when Haloperidol is combined with Isocarboxazid. |
Ramelteon | Ramelteon The risk or severity of CNS depression can be increased when Haloperidol is combined with Ramelteon. |
Darifenacin | Darifenacin The serum concentration of Darifenacin can be increased when it is combined with Haloperidol. |
Fentanyl | Fentanyl The metabolism of Fentanyl can be decreased when combined with Haloperidol. |
Pregabalin | Pregabalin The therapeutic efficacy of Haloperidol can be increased when used in combination with Pregabalin. |
Deferasirox | Deferasirox The serum concentration of Haloperidol can be increased when it is combined with Deferasirox. |
Phenylephrine | Phenylephrine The metabolism of Haloperidol can be increased when combined with Phenylephrine. |
Tipranavir | Tipranavir The serum concentration of Tipranavir can be increased when it is combined with Haloperidol. |
Felbamate | Felbamate The risk or severity of QTc prolongation can be increased when Felbamate is combined with Haloperidol. |
Insulin Detemir (rDNA Origin) Injection | Insulin Detemir (rDNA Origin) Injection The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Haloperidol. |
Ranolazine | Ranolazine The metabolism of Ranolazine can be decreased when combined with Haloperidol. |
Abatacept Injection | Abatacept Injection The metabolism of Haloperidol can be increased when combined with Abatacept. |
Rasagiline | Rasagiline The risk or severity of CNS depression can be increased when Rasagiline is combined with Haloperidol. |
Imatinib | Imatinib The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Imatinib. |
Sitagliptin | Sitagliptin The serum concentration of Sitagliptin can be increased when it is combined with Haloperidol. |
Varenicline | Varenicline Haloperidol may decrease the excretion rate of Varenicline which could result in a higher serum level. |
Gefitinib | Gefitinib The serum concentration of Haloperidol can be increased when it is combined with Gefitinib. |
Albuterol | Albuterol The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Haloperidol. |
Paliperidone | Paliperidone The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Paliperidone. |
Exemestane | Exemestane The serum concentration of Haloperidol can be increased when it is combined with Exemestane. |
Bortezomib | Bortezomib The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Haloperidol. |
Clofarabine Injection | Clofarabine Injection Haloperidol may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
Insulin Glulisine (rDNA origin) Injection | Insulin Glulisine (rDNA origin) Injection The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Haloperidol. |
Lubiprostone | Lubiprostone Haloperidol may decrease the excretion rate of Lubiprostone which could result in a higher serum level. |
Oxaliplatin Injection | Oxaliplatin Injection The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Oxaliplatin. |
Posaconazole | Posaconazole The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Haloperidol. |
Primaquine | Primaquine The risk or severity of QTc prolongation can be increased when Primaquine is combined with Haloperidol. |
Aliskiren | Aliskiren The serum concentration of Haloperidol can be increased when it is combined with Aliskiren. |
Bismuth Subsalicylate | Bismuth Subsalicylate Haloperidol may increase the neurotoxic activities of Bismuth subsalicylate. |
Darunavir | Darunavir The serum concentration of Darunavir can be increased when it is combined with Haloperidol. |
Pemetrexed Injection | Pemetrexed Injection Haloperidol may decrease the excretion rate of Pemetrexed which could result in a higher serum level. |
Dimenhydrinate | Dimenhydrinate The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Dimenhydrinate. |
Lisdexamfetamine | Lisdexamfetamine The therapeutic efficacy of Lisdexamfetamine can be decreased when used in combination with Haloperidol. |
Nabilone | Nabilone The risk or severity of CNS depression can be increased when Nabilone is combined with Haloperidol. |
Retapamulin | Retapamulin The metabolism of Retapamulin can be decreased when combined with Haloperidol. |
Vorinostat | Vorinostat The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Haloperidol. |
Sorafenib | Sorafenib The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Haloperidol. |
Sunitinib | Sunitinib The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Haloperidol. |
Dronabinol | Dronabinol The risk or severity of CNS depression can be increased when Dronabinol is combined with Haloperidol. |
Lapatinib | Lapatinib The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Lapatinib. |
Levocetirizine | Levocetirizine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Levocetirizine. |
Pegaptanib Injection | Pegaptanib Injection Haloperidol may decrease the excretion rate of Pegaptanib which could result in a higher serum level. |
Dasatinib | Dasatinib The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Dasatinib. |
Mexiletine | Mexiletine The serum concentration of Haloperidol can be increased when it is combined with Mexiletine. |
Armodafinil | Armodafinil The metabolism of Haloperidol can be increased when combined with Armodafinil. |
Azacitidine Injection | Azacitidine Injection Haloperidol may decrease the excretion rate of Azacitidine which could result in a higher serum level. |
Ivermectin | Ivermectin The serum concentration of Haloperidol can be increased when it is combined with Ivermectin. |
Temsirolimus | Temsirolimus The serum concentration of Temsirolimus can be increased when it is combined with Haloperidol. |
Maraviroc | Maraviroc The serum concentration of Maraviroc can be increased when it is combined with Haloperidol. |
Lenalidomide | Lenalidomide Lenalidomide may decrease the excretion rate of Haloperidol which could result in a higher serum level. |
Nilotinib | Nilotinib The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Nilotinib. |
Toremifene | Toremifene The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Toremifene. |
Bexarotene | Bexarotene The serum concentration of Haloperidol can be increased when it is combined with Bexarotene. |
Budesonide | Budesonide The serum concentration of Haloperidol can be increased when it is combined with Budesonide. |
Chloramphenicol Injection | Chloramphenicol Injection The serum concentration of Haloperidol can be increased when it is combined with Chloramphenicol. |
Desmopressin | Desmopressin Desmopressin may decrease the excretion rate of Haloperidol which could result in a higher serum level. |
OnabotulinumtoxinA Injection | OnabotulinumtoxinA Injection The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Haloperidol. |
RimabotulinumtoxinB Injection | RimabotulinumtoxinB Injection The risk or severity of CNS depression can be increased when Botulinum Toxin Type B is combined with Haloperidol. |
Doripenem Injection | Doripenem Injection Haloperidol may decrease the excretion rate of Doripenem which could result in a higher serum level. |
Etravirine | Etravirine The serum concentration of Haloperidol can be increased when it is combined with Etravirine. |
Arsenic Trioxide Injection | Arsenic Trioxide Injection The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Arsenic trioxide. |
Mitoxantrone Injection | Mitoxantrone Injection The serum concentration of Haloperidol can be increased when it is combined with Mitoxantrone. |
Desvenlafaxine | Desvenlafaxine The risk or severity of CNS depression can be increased when Haloperidol is combined with Desvenlafaxine. |
Cevimeline | Cevimeline The serum concentration of Cevimeline can be increased when it is combined with Haloperidol. |
Nebivolol | Nebivolol The serum concentration of Nebivolol can be increased when it is combined with Haloperidol. |
Tretinoin | Tretinoin The serum concentration of Tretinoin can be increased when it is combined with Haloperidol. |
Bendamustine Injection | Bendamustine Injection The metabolism of Bendamustine can be decreased when combined with Haloperidol. |
Pilocarpine | Pilocarpine The serum concentration of Haloperidol can be increased when it is combined with Pilocarpine. |
Flecainide | Flecainide The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Flecainide. |
Certolizumab Injection | Certolizumab Injection The metabolism of Haloperidol can be increased when combined with Certolizumab pegol. |
Ixabepilone Injection | Ixabepilone Injection The serum concentration of Ixabepilone can be increased when it is combined with Haloperidol. |
Irinotecan Injection | Irinotecan Injection The serum concentration of Irinotecan can be increased when it is combined with Haloperidol. |
Daptomycin Injection | Daptomycin Injection Daptomycin may decrease the excretion rate of Haloperidol which could result in a higher serum level. |
Estramustine | Estramustine The serum concentration of Haloperidol can be increased when it is combined with Estramustine. |
Praziquantel | Praziquantel The serum concentration of Praziquantel can be increased when it is combined with Haloperidol. |
Methylnaltrexone Injection | Methylnaltrexone Injection Haloperidol may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level. |
Rufinamide | Rufinamide The risk or severity of CNS depression can be increased when Rufinamide is combined with Haloperidol. |
Silodosin | Silodosin The serum concentration of Haloperidol can be increased when it is combined with Silodosin. |
Midazolam | Midazolam The serum concentration of Midazolam can be increased when it is combined with Haloperidol. |
Dexrazoxane Injection | Dexrazoxane Injection Dexrazoxane may decrease the excretion rate of Haloperidol which could result in a higher serum level. |
Eltrombopag | Eltrombopag The metabolism of Haloperidol can be decreased when combined with Eltrombopag. |
Milnacipran | Milnacipran The risk or severity of CNS depression can be increased when Haloperidol is combined with Milnacipran. |
Dexlansoprazole | Dexlansoprazole The serum concentration of Haloperidol can be increased when it is combined with Dexlansoprazole. |
Plerixafor Injection | Plerixafor Injection Haloperidol may decrease the excretion rate of Plerixafor which could result in a higher serum level. |
Fesoterodine | Fesoterodine The serum concentration of Fesoterodine can be increased when it is combined with Haloperidol. |
Degarelix Injection | Degarelix Injection The risk or severity of QTc prolongation can be increased when Degarelix is combined with Haloperidol. |
Betaxolol | Betaxolol The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Haloperidol. |
Iloperidone | Iloperidone The metabolism of Iloperidone can be decreased when combined with Haloperidol. |
Prasugrel | Prasugrel The serum concentration of Prasugrel can be increased when it is combined with Haloperidol. |
Lacosamide | Lacosamide The risk or severity of CNS depression can be increased when Haloperidol is combined with Lacosamide. |
Everolimus | Everolimus The metabolism of Everolimus can be decreased when combined with Haloperidol. |
Tolvaptan (low blood sodium) | Tolvaptan (low blood sodium) The serum concentration of Tolvaptan can be increased when it is combined with Haloperidol. |
Dronedarone | Dronedarone The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Dronedarone. |
AbobotulinumtoxinA Injection | AbobotulinumtoxinA Injection The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Haloperidol. |
Pralatrexate Injection | Pralatrexate Injection Haloperidol may decrease the excretion rate of Pralatrexate which could result in a higher serum level. |
Palonosetron Injection | Palonosetron Injection The risk or severity of CNS depression can be increased when Haloperidol is combined with Palonosetron. |
Saxagliptin | Saxagliptin The serum concentration of Saxagliptin can be increased when it is combined with Haloperidol. |
Telavancin Injection | Telavancin Injection The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Telavancin. |
Romidepsin Injection | Romidepsin Injection The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Romidepsin. |
Tapentadol | Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Haloperidol. |
Topotecan | Topotecan The serum concentration of Topotecan can be increased when it is combined with Haloperidol. |
Golimumab Injection | Golimumab Injection The metabolism of Haloperidol can be increased when combined with Golimumab. |
Pazopanib | Pazopanib The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Pazopanib. |
Asenapine | Asenapine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Asenapine. |
Vigabatrin | Vigabatrin The risk or severity of CNS depression can be increased when Haloperidol is combined with Vigabatrin. |
Pitavastatin | Pitavastatin The metabolism of Pitavastatin can be decreased when combined with Haloperidol. |
Albendazole | Albendazole The serum concentration of Albendazole can be increased when it is combined with Haloperidol. |
Ulipristal | Ulipristal The serum concentration of Haloperidol can be increased when it is combined with Ulipristal. |
Levonorgestrel | Levonorgestrel The serum concentration of Haloperidol can be increased when it is combined with Levonorgestrel. |
Oxymorphone | Oxymorphone The risk or severity of CNS depression can be increased when Haloperidol is combined with Oxymorphone. |
Liraglutide Injection | Liraglutide Injection The therapeutic efficacy of Liraglutide can be decreased when used in combination with Haloperidol. |
Tocilizumab Injection | Tocilizumab Injection The metabolism of Haloperidol can be increased when combined with Tocilizumab. |
Dalfampridine | Dalfampridine The risk or severity of seizure can be increased when Haloperidol is combined with Dalfampridine. |
Fingolimod | Fingolimod The risk or severity of QTc prolongation can be increased when Fingolimod is combined with Haloperidol. |
Eribulin Injection | Eribulin Injection The risk or severity of QTc prolongation can be increased when Eribulin is combined with Haloperidol. |
IncobotulinumtoxinA Injection | IncobotulinumtoxinA Injection The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Haloperidol. |
Cabazitaxel Injection | Cabazitaxel Injection The serum concentration of Cabazitaxel can be increased when it is combined with Haloperidol. |
Ceftaroline Injection | Ceftaroline Injection Ceftaroline fosamil may decrease the excretion rate of Haloperidol which could result in a higher serum level. |
Lurasidone | Lurasidone The metabolism of Lurasidone can be decreased when combined with Haloperidol. |
Acetaminophen Injection | Acetaminophen Injection The serum concentration of Haloperidol can be increased when it is combined with Acetaminophen. |
Vilazodone | Vilazodone The risk or severity of CNS depression can be increased when Haloperidol is combined with Vilazodone. |
Ipilimumab Injection | Ipilimumab Injection Haloperidol may decrease the excretion rate of Ipilimumab which could result in a higher serum level. |
Denileukin Diftitox Injection | Denileukin Diftitox Injection The serum concentration of Haloperidol can be increased when it is combined with Aldesleukin. |
Terbutaline Injection | Terbutaline Injection The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Haloperidol. |
Busulfan Injection | Busulfan Injection The serum concentration of Busulfan can be increased when it is combined with Haloperidol. |
Roflumilast | Roflumilast The serum concentration of Roflumilast can be increased when it is combined with Haloperidol. |
Linagliptin | Linagliptin The serum concentration of Linagliptin can be increased when it is combined with Haloperidol. |
Rilpivirine | Rilpivirine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Rilpivirine. |
Cyclophosphamide Injection | Cyclophosphamide Injection The serum concentration of Cyclophosphamide can be increased when it is combined with Haloperidol. |
Abiraterone | Abiraterone The serum concentration of Haloperidol can be increased when it is combined with Abiraterone. |
Triptorelin Injection | Triptorelin Injection The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Haloperidol. |
Rivaroxaban | Rivaroxaban The serum concentration of Rivaroxaban can be increased when it is combined with Haloperidol. |
Ticagrelor | Ticagrelor The serum concentration of Ticagrelor can be increased when it is combined with Haloperidol. |
Brentuximab Vedotin Injection | Brentuximab Vedotin Injection The serum concentration of Haloperidol can be increased when it is combined with Brentuximab vedotin. |
Ruxolitinib | Ruxolitinib The serum concentration of Ruxolitinib can be increased when it is combined with Haloperidol. |
Vandetanib | Vandetanib The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Vandetanib. |
Clobazam | Clobazam The risk or severity of CNS depression can be increased when Clobazam is combined with Haloperidol. |
Vemurafenib | Vemurafenib The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Haloperidol. |
Vismodegib | Vismodegib The serum concentration of Haloperidol can be increased when it is combined with Vismodegib. |
Ivacaftor | Ivacaftor The metabolism of Haloperidol can be decreased when combined with Ivacaftor. |
Deferiprone | Deferiprone Haloperidol may decrease the excretion rate of Deferiprone which could result in a higher serum level. |
Axitinib | Axitinib The serum concentration of Axitinib can be increased when it is combined with Haloperidol. |
Crizotinib | Crizotinib The risk or severity of QTc prolongation can be increased when Crizotinib is combined with Haloperidol. |
Cabergoline | Cabergoline The risk or severity of CNS depression can be increased when Cabergoline is combined with Haloperidol. |
Naloxone Injection | Naloxone Injection The serum concentration of Naloxone can be increased when it is combined with Haloperidol. |
Ambrisentan | Ambrisentan The serum concentration of Ambrisentan can be increased when it is combined with Haloperidol. |
Fondaparinux Injection | Fondaparinux Injection Haloperidol may decrease the excretion rate of Fondaparinux which could result in a higher serum level. |
Ezogabine | Ezogabine The risk or severity of CNS depression can be increased when Haloperidol is combined with Tiagabine. |
Enzalutamide | Enzalutamide The serum concentration of Haloperidol can be increased when it is combined with Enzalutamide. |
Mirabegron | Mirabegron The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Mirabegron. |
Regorafenib | Regorafenib The serum concentration of Haloperidol can be increased when it is combined with Regorafenib. |
Bosutinib | Bosutinib The serum concentration of Haloperidol can be increased when it is combined with Bosutinib. |
Corticotropin, Repository Injection | Corticotropin, Repository Injection The serum concentration of Haloperidol can be increased when it is combined with Corticotropin. |
Teriflunomide | Teriflunomide The serum concentration of Haloperidol can be decreased when it is combined with Teriflunomide. |
Lorcaserin | Lorcaserin The therapeutic efficacy of Mecasermin can be decreased when used in combination with Haloperidol. |
Cabozantinib (thyroid cancer) | Cabozantinib (thyroid cancer) The serum concentration of Cabozantinib can be increased when it is combined with Haloperidol. |
Teduglutide Injection | Teduglutide Injection Haloperidol may decrease the excretion rate of Teduglutide which could result in a higher serum level. |
Bedaquiline | Bedaquiline The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Bedaquiline. |
Tofacitinib | Tofacitinib The metabolism of Tofacitinib can be decreased when combined with Haloperidol. |
Alogliptin | Alogliptin The serum concentration of Alogliptin can be increased when it is combined with Haloperidol. |
Ponatinib | Ponatinib The serum concentration of Ponatinib can be increased when it is combined with Haloperidol. |
Pomalidomide | Pomalidomide The risk or severity of CNS depression can be increased when Haloperidol is combined with Pomalidomide. |
Ado-trastuzumab Emtansine Injection | Ado-trastuzumab Emtansine Injection The serum concentration of Trastuzumab emtansine can be increased when it is combined with Haloperidol. |
Apixaban | Apixaban The serum concentration of Apixaban can be increased when it is combined with Haloperidol. |
Canagliflozin | Canagliflozin The serum concentration of Canagliflozin can be increased when it is combined with Haloperidol. |
Methazolamide | Methazolamide Methazolamide may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy. |
Dabrafenib | Dabrafenib The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Haloperidol. |
Ospemifene | Ospemifene The serum concentration of Ospemifene can be increased when it is combined with Haloperidol. |
Trametinib | Trametinib Haloperidol may decrease the excretion rate of Trametinib which could result in a higher serum level. |
Levomilnacipran | Levomilnacipran The risk or severity of CNS depression can be increased when Haloperidol is combined with Levomilnacipran. |
Ertapenem Injection | Ertapenem Injection Ertapenem may decrease the excretion rate of Haloperidol which could result in a higher serum level. |
Vortioxetine | Vortioxetine The risk or severity of CNS depression can be increased when Haloperidol is combined with Vortioxetine. |
Perampanel | Perampanel The risk or severity of CNS depression can be increased when Perampanel is combined with Haloperidol. |
Ibrutinib | Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Haloperidol. |
Lomitapide | Lomitapide The serum concentration of Lomitapide can be increased when it is combined with Haloperidol. |
Avanafil | Avanafil The metabolism of Avanafil can be decreased when combined with Haloperidol. |
Ketorolac Injection | Ketorolac Injection The therapeutic efficacy of Haloperidol can be increased when used in combination with Ketorolac. |
Simeprevir | Simeprevir The serum concentration of Haloperidol can be increased when it is combined with Simeprevir. |
Sofosbuvir | Sofosbuvir Haloperidol may decrease the excretion rate of Sofosbuvir which could result in a higher serum level. |
Dapagliflozin | Dapagliflozin The serum concentration of Haloperidol can be increased when it is combined with Dapagliflozin. |
Apremilast | Apremilast The serum concentration of Haloperidol can be increased when it is combined with Apremilast. |
Droxidopa | Droxidopa Haloperidol may decrease the excretion rate of Droxidopa which could result in a higher serum level. |
Ceritinib | Ceritinib The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Haloperidol. |
Siltuximab Injection | Siltuximab Injection The serum concentration of Haloperidol can be increased when it is combined with Siltuximab. |
Albiglutide Injection | Albiglutide Injection The therapeutic efficacy of Albiglutide can be decreased when used in combination with Haloperidol. |
Eslicarbazepine | Eslicarbazepine The risk or severity of CNS depression can be increased when Haloperidol is combined with Eslicarbazepine. |
Belinostat Injection | Belinostat Injection The metabolism of Haloperidol can be increased when combined with Belinostat. |
Idelalisib | Idelalisib The serum concentration of Haloperidol can be increased when it is combined with Idelalisib. |
Testosterone Injection | Testosterone Injection The serum concentration of Testosterone can be increased when it is combined with Haloperidol. |
Oritavancin Injection | Oritavancin Injection The serum concentration of Haloperidol can be increased when it is combined with Oritavancin. |
Empagliflozin | Empagliflozin The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Haloperidol. |
Vorapaxar | Vorapaxar The serum concentration of Haloperidol can be increased when it is combined with Vorapaxar. |
Hydrocodone | Hydrocodone Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
Suvorexant | Suvorexant Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
Dulaglutide Injection | Dulaglutide Injection The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Haloperidol. |
Edoxaban | Edoxaban Haloperidol may decrease the excretion rate of Edoxaban which could result in a higher serum level. |
Peginterferon Beta-1a Injection | Peginterferon Beta-1a Injection The metabolism of Haloperidol can be decreased when combined with Peginterferon beta-1a. |
Olaparib | Olaparib The metabolism of Olaparib can be decreased when combined with Haloperidol. |
Methamphetamine | Methamphetamine The therapeutic efficacy of Metamfetamine can be decreased when used in combination with Haloperidol. |
Tasimelteon | Tasimelteon The risk or severity of CNS depression can be increased when Haloperidol is combined with Tasimelteon. |
Riociguat | Riociguat The serum concentration of Haloperidol can be increased when it is combined with Riociguat. |
Lanreotide Injection | Lanreotide Injection The serum concentration of Haloperidol can be increased when it is combined with Lanreotide. |
Pirfenidone | Pirfenidone The metabolism of Pirfenidone can be decreased when combined with Haloperidol. |
Nintedanib | Nintedanib The serum concentration of Haloperidol can be increased when it is combined with Nintedanib. |
Secukinumab Injection | Secukinumab Injection The metabolism of Haloperidol can be increased when combined with Secukinumab. |
Risperidone Injection | Risperidone Injection The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Risperidone. |
Palbociclib | Palbociclib The serum concentration of Haloperidol can be increased when it is combined with Palbociclib. |
Insulin Human Inhalation | Insulin Human Inhalation The therapeutic efficacy of Insulin human can be decreased when used in combination with Haloperidol. |
Lenvatinib | Lenvatinib The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Haloperidol. |
Naloxegol | Naloxegol The metabolism of Naloxegol can be decreased when combined with Haloperidol. |
Panobinostat | Panobinostat The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Panobinostat. |
Ivabradine | Ivabradine The metabolism of Ivabradine can be decreased when combined with Haloperidol. |
Amiloride | Amiloride Amiloride may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy. |
Isavuconazonium Injection | Isavuconazonium Injection The serum concentration of Haloperidol can be increased when it is combined with Isavuconazonium. |
Macitentan | Macitentan The serum concentration of Macitentan can be increased when it is combined with Haloperidol. |
Sonidegib | Sonidegib The metabolism of Sonidegib can be decreased when combined with Haloperidol. |
Flibanserin | Flibanserin The metabolism of Haloperidol can be decreased when combined with Flibanserin. |
Rolapitant | Rolapitant The serum concentration of Rolapitant can be increased when it is combined with Haloperidol. |
Prednisolone | Prednisolone The serum concentration of Haloperidol can be increased when it is combined with Prednisolone. |
Daclatasvir | Daclatasvir The serum concentration of Daclatasvir can be increased when it is combined with Haloperidol. |
Brexpiprazole | Brexpiprazole The metabolism of Brexpiprazole can be decreased when combined with Haloperidol. |
Ziprasidone Injection | Ziprasidone Injection The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Haloperidol. |
Cariprazine | Cariprazine The risk or severity of CNS depression can be increased when Haloperidol is combined with Cariprazine. |
Penicillin G Procaine Injection | Penicillin G Procaine Injection Haloperidol may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level. |
Insulin Degludec (rDNA Origin) Injection | Insulin Degludec (rDNA Origin) Injection The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Haloperidol. |
Cobimetinib | Cobimetinib The metabolism of Cobimetinib can be decreased when combined with Haloperidol. |
Trabectedin Injection | Trabectedin Injection The serum concentration of Trabectedin can be increased when it is combined with Haloperidol. |
Osimertinib | Osimertinib The serum concentration of Haloperidol can be increased when it is combined with Osimertinib. |
Alectinib | Alectinib The metabolism of Alectinib can be decreased when combined with Haloperidol. |
Ixazomib | Ixazomib The serum concentration of Ixazomib can be increased when it is combined with Haloperidol. |
Rifapentine | Rifapentine The serum concentration of Haloperidol can be increased when it is combined with Rifapentine. |
Lesinurad | Lesinurad Haloperidol may decrease the excretion rate of Lesinurad which could result in a higher serum level. |
Amphotericin B Liposomal Injection | Amphotericin B Liposomal Injection The serum concentration of Haloperidol can be increased when it is combined with Amphotericin B. |
Dexamethasone Injection | Dexamethasone Injection The serum concentration of Haloperidol can be increased when it is combined with Dexamethasone. |
Brivaracetam Injection | Brivaracetam Injection The risk or severity of CNS depression can be increased when Haloperidol is combined with Brivaracetam. |
Venetoclax | Venetoclax The serum concentration of Haloperidol can be increased when it is combined with Venetoclax. |
Cobicistat | Cobicistat The serum concentration of Haloperidol can be increased when it is combined with Cobicistat. |
Selexipag | Selexipag The serum concentration of Haloperidol can be increased when it is combined with Selexipag. |
Pimavanserin | Pimavanserin The risk or severity of CNS depression can be increased when Haloperidol is combined with Pimavanserin. |
Obeticholic Acid | Obeticholic Acid The metabolism of Haloperidol can be decreased when combined with Obeticholic acid. |
Diphenhydramine Injection | Diphenhydramine Injection The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Diphenhydramine. |
Furosemide Injection | Furosemide Injection Haloperidol may increase the excretion rate of Furosemide which could result in a lower serum level and potentially a reduction in efficacy. |
Rucaparib | Rucaparib The serum concentration of Rucaparib can be increased when it is combined with Haloperidol. |
Lixisenatide Injection | Lixisenatide Injection The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Haloperidol. |
Ribociclib | Ribociclib The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Ribociclib. |
Brigatinib | Brigatinib The serum concentration of Haloperidol can be increased when it is combined with Brigatinib. |
Doxepin (Insomnia) | Doxepin (Insomnia) The serum concentration of Doxepin can be increased when it is combined with Haloperidol. |
Deutetrabenazine | Deutetrabenazine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Deutetrabenazine. |
Valbenazine | Valbenazine The serum concentration of Valbenazine can be increased when it is combined with Haloperidol. |
Deflazacort | Deflazacort The serum concentration of Haloperidol can be increased when it is combined with Deflazacort. |
Safinamide | Safinamide The risk or severity of CNS depression can be increased when Safinamide is combined with Haloperidol. |
Naldemedine | Naldemedine Haloperidol may decrease the excretion rate of Naldemedine which could result in a higher serum level. |
Sarilumab Injection | Sarilumab Injection The serum concentration of Haloperidol can be increased when it is combined with Sarilumab. |
Midostaurin | Midostaurin The serum concentration of Haloperidol can be increased when it is combined with Midostaurin. |
Neratinib | Neratinib The serum concentration of Haloperidol can be increased when it is combined with Neratinib. |
Enasidenib | Enasidenib The serum concentration of Haloperidol can be increased when it is combined with Enasidenib. |
Aprepitant/Fosaprepitant Injection | Aprepitant/Fosaprepitant Injection The serum concentration of Fosaprepitant can be increased when it is combined with Haloperidol. |
Benznidazole | Benznidazole Haloperidol may decrease the excretion rate of Benznidazole which could result in a higher serum level. |
Copanlisib Injection | Copanlisib Injection The serum concentration of Copanlisib can be increased when it is combined with Haloperidol. |
Delafloxacin | Delafloxacin The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Haloperidol. |
Abemaciclib | Abemaciclib The serum concentration of Haloperidol can be increased when it is combined with Abemaciclib. |
Acalabrutinib | Acalabrutinib The serum concentration of Haloperidol can be increased when it is combined with Acalabrutinib. |
Letermovir | Letermovir The serum concentration of Letermovir can be increased when it is combined with Haloperidol. |
Semaglutide Injection | Semaglutide Injection The therapeutic efficacy of Semaglutide can be decreased when used in combination with Haloperidol. |
Tetrabenazine | Tetrabenazine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Tetrabenazine. |
Ertugliflozin | Ertugliflozin The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Haloperidol. |
Buprenorphine Injection | Buprenorphine Injection Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Apalutamide | Apalutamide The serum concentration of Haloperidol can be increased when it is combined with Apalutamide. |
Fostamatinib | Fostamatinib The serum concentration of Haloperidol can be increased when it is combined with Fostamatinib. |
Avatrombopag | Avatrombopag The metabolism of Haloperidol can be increased when combined with Avatrombopag. |
Baricitinib | Baricitinib The serum concentration of Baricitinib can be increased when it is combined with Haloperidol. |
Lofexidine | Lofexidine The therapeutic efficacy of Haloperidol can be increased when used in combination with Lofexidine. |
Plazomicin Injection | Plazomicin Injection Haloperidol may decrease the excretion rate of Plazomicin which could result in a higher serum level. |
Eliglustat | Eliglustat The metabolism of Eliglustat can be decreased when combined with Haloperidol. |
Encorafenib | Encorafenib The serum concentration of Encorafenib can be increased when it is combined with Haloperidol. |
Binimetinib | Binimetinib The metabolism of Binimetinib can be decreased when combined with Haloperidol. |
Ivosidenib | Ivosidenib The risk or severity of QTc prolongation can be increased when Ivosidenib is combined with Haloperidol. |
Elagolix | Elagolix The serum concentration of Elagolix can be increased when it is combined with Haloperidol. |
Eravacycline Injection | Eravacycline Injection The serum concentration of Haloperidol can be increased when it is combined with Eravacycline. |
Doravirine | Doravirine The serum concentration of Doravirine can be increased when it is combined with Haloperidol. |
Tafenoquine | Tafenoquine The serum concentration of Tafenoquine can be increased when it is combined with Haloperidol. |
Cannabidiol | Cannabidiol The risk or severity of CNS depression can be increased when Cannabidiol is combined with Haloperidol. |
Dacomitinib | Dacomitinib The serum concentration of Haloperidol can be increased when it is combined with Dacomitinib. |
Duvelisib | Duvelisib The serum concentration of Haloperidol can be increased when it is combined with Duvelisib. |
Stiripentol | Stiripentol The risk or severity of CNS depression can be increased when Stiripentol is combined with Haloperidol. |
Gilteritinib | Gilteritinib The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Haloperidol. |
Glasdegib | Glasdegib The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Glasdegib. |
Lorlatinib | Lorlatinib The metabolism of Lorlatinib can be decreased when combined with Haloperidol. |
Larotrectinib | Larotrectinib The serum concentration of Haloperidol can be increased when it is combined with Larotrectinib. |
Paclitaxel (with albumin) Injection | Paclitaxel (with albumin) Injection The serum concentration of Paclitaxel can be increased when it is combined with Haloperidol. |
Rifamycin | Rifamycin The serum concentration of Haloperidol can be increased when it is combined with Rifamycin. |
Prucalopride | Prucalopride The serum concentration of Prucalopride can be increased when it is combined with Haloperidol. |
Emapalumab-lzsg Injection | Emapalumab-lzsg Injection The metabolism of Haloperidol can be increased when combined with Emapalumab. |
Siponimod | Siponimod The risk or severity of adverse effects can be increased when Haloperidol is combined with Siponimod. |
Acyclovir Ophthalmic | Acyclovir Ophthalmic Acyclovir may decrease the excretion rate of Haloperidol which could result in a higher serum level. |
Erdafitinib | Erdafitinib The serum concentration of Erdafitinib can be increased when it is combined with Haloperidol. |
Esomeprazole Injection | Esomeprazole Injection The serum concentration of Haloperidol can be increased when it is combined with Esomeprazole. |
Alpelisib | Alpelisib The serum concentration of Haloperidol can be increased when it is combined with Alpelisib. |
Brexanolone Injection | Brexanolone Injection The risk or severity of CNS depression can be increased when Haloperidol is combined with Brexanolone. |
Polatuzumab vedotin-piiq Injection | Polatuzumab vedotin-piiq Injection The serum concentration of Haloperidol can be increased when it is combined with Polatuzumab vedotin. |
Solriamfetol | Solriamfetol The risk or severity of CNS depression can be increased when Haloperidol is combined with Solriamfetol. |
Selinexor | Selinexor The serum concentration of Haloperidol can be increased when it is combined with Selinexor. |
Darolutamide | Darolutamide The serum concentration of Haloperidol can be increased when it is combined with Darolutamide. |
Triclabendazole | Triclabendazole The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Haloperidol. |
Entrectinib | Entrectinib The metabolism of Entrectinib can be decreased when combined with Haloperidol. |
Pexidartinib | Pexidartinib The metabolism of Pexidartinib can be decreased when combined with Haloperidol. |
Upadacitinib | Upadacitinib The serum concentration of Haloperidol can be increased when it is combined with Upadacitinib. |
Istradefylline | Istradefylline The serum concentration of Istradefylline can be increased when it is combined with Haloperidol. |
Pitolisant | Pitolisant The serum concentration of Haloperidol can be decreased when it is combined with Pitolisant. |
Pretomanid | Pretomanid The serum concentration of Pretomanid can be increased when it is combined with Haloperidol. |
Fedratinib | Fedratinib The serum concentration of Haloperidol can be increased when it is combined with Fedratinib. |
Lefamulin | Lefamulin Haloperidol may increase the QTc-prolonging activities of Lefamulin. |
Phenytoin Injection | Phenytoin Injection The risk or severity of CNS depression can be increased when Phenytoin is combined with Haloperidol. |
Fosphenytoin Injection | Fosphenytoin Injection The risk or severity of CNS depression can be increased when Haloperidol is combined with Fosphenytoin. |
Enfortumab vedotin-ejfv Injection | Enfortumab vedotin-ejfv Injection The serum concentration of Haloperidol can be increased when it is combined with Enfortumab vedotin. |
Zanubrutinib | Zanubrutinib The metabolism of Zanubrutinib can be decreased when combined with Haloperidol. |
Voxelotor | Voxelotor The serum concentration of Voxelotor can be increased when it is combined with Haloperidol. |
Avapritinib | Avapritinib The serum concentration of Avapritinib can be increased when it is combined with Haloperidol. |
Lumateperone | Lumateperone The serum concentration of Lumateperone can be increased when it is combined with Haloperidol. |
Lasmiditan | Lasmiditan The risk or severity of CNS depression can be increased when Haloperidol is combined with Lasmiditan. |
Ubrogepant | Ubrogepant The serum concentration of Ubrogepant can be increased when it is combined with Haloperidol. |
Tazemetostat | Tazemetostat The serum concentration of Haloperidol can be increased when it is combined with Tazemetostat. |
Cenobamate | Cenobamate The serum concentration of Haloperidol can be decreased when it is combined with Cenobamate. |
Pemigatinib | Pemigatinib The metabolism of Pemigatinib can be decreased when combined with Haloperidol. |
Selumetinib | Selumetinib The serum concentration of Selumetinib can be increased when it is combined with Haloperidol. |
Rimegepant | Rimegepant The metabolism of Rimegepant can be decreased when combined with Haloperidol. |
Tucatinib | Tucatinib The metabolism of Tucatinib can be decreased when combined with Haloperidol. |
Remdesivir Injection | Remdesivir Injection The serum concentration of Haloperidol can be increased when it is combined with Remdesivir. |
Ripretinib | Ripretinib The serum concentration of Haloperidol can be increased when it is combined with Ripretinib. |
Selpercatinib | Selpercatinib The risk or severity of QTc prolongation can be increased when Selpercatinib is combined with Haloperidol. |
Capmatinib | Capmatinib The serum concentration of Haloperidol can be increased when it is combined with Capmatinib. |
Lemborexant | Lemborexant The risk or severity of CNS depression can be increased when Haloperidol is combined with Lemborexant. |
Fenfluramine | Fenfluramine The risk or severity of CNS depression can be increased when Fenfluramine is combined with Haloperidol. |
Fostemsavir | Fostemsavir The serum concentration of Haloperidol can be increased when it is combined with Fostemsavir. |
Lurbinectedin Injection | Lurbinectedin Injection The serum concentration of Lurbinectedin can be increased when it is combined with Haloperidol. |
Octreotide | Octreotide The risk or severity of QTc prolongation can be increased when Octreotide is combined with Haloperidol. |
Pralsetinib | Pralsetinib The serum concentration of Haloperidol can be increased when it is combined with Pralsetinib. |
Opicapone | Opicapone The therapeutic efficacy of Opicapone can be decreased when used in combination with Haloperidol. |
Satralizumab-mwge Injection | Satralizumab-mwge Injection The serum concentration of Haloperidol can be decreased when it is combined with Satralizumab. |
Naxitamab-gqgk Injection | Naxitamab-gqgk Injection Haloperidol may increase the neurotoxic activities of Naxitamab. |
Relugolix | Relugolix The risk or severity of QTc prolongation can be increased when Relugolix is combined with Haloperidol. |
Progestin-Only (drospirenone) Oral Contraceptives | Progestin-Only (drospirenone) Oral Contraceptives The serum concentration of Haloperidol can be increased when it is combined with Drospirenone. |
Viloxazine | Viloxazine The risk or severity of CNS depression can be increased when Haloperidol is combined with Viloxazine. |
Vitamin E (Alpha-Tocopherol) | Vitamin E (Alpha-Tocopherol) The serum concentration of Haloperidol can be increased when it is combined with Vitamin E. |
Tobramycin Injection | Tobramycin Injection Tobramycin may decrease the excretion rate of Haloperidol which could result in a higher serum level. |
Theophylline | Theophylline The serum concentration of Theophylline can be increased when it is combined with Haloperidol. |
Fenoprofen | Fenoprofen The therapeutic efficacy of Haloperidol can be increased when used in combination with Fenoprofen. |
Indomethacin | Indomethacin The therapeutic efficacy of Haloperidol can be increased when used in combination with Indomethacin. |
Mefenamic Acid | Mefenamic Acid The therapeutic efficacy of Haloperidol can be increased when used in combination with Mefenamic acid. |
Naproxen | Naproxen The therapeutic efficacy of Haloperidol can be increased when used in combination with Naproxen. |
Tolmetin | Tolmetin The therapeutic efficacy of Haloperidol can be increased when used in combination with Tolmetin. |
Sulindac | Sulindac The therapeutic efficacy of Haloperidol can be increased when used in combination with Sulindac. |
Trazodone | Trazodone The risk or severity of QTc prolongation can be increased when Trazodone is combined with Haloperidol. |
Isotretinoin | Isotretinoin The serum concentration of Isotretinoin can be increased when it is combined with Haloperidol. |
Sucralfate | Sucralfate Sucralfate may decrease the excretion rate of Haloperidol which could result in a higher serum level. |
Hydroxyurea | Hydroxyurea The serum concentration of Haloperidol can be increased when it is combined with Hydroxyurea. |
Floxuridine | Floxuridine The metabolism of Haloperidol can be decreased when combined with Floxuridine. |
Phenobarbital | Phenobarbital The risk or severity of CNS depression can be increased when Haloperidol is combined with Phenobarbital. |
Metaxalone | Metaxalone The risk or severity of CNS depression can be increased when Haloperidol is combined with Metaxalone. |
Methotrexate Injection | Methotrexate Injection The serum concentration of Haloperidol can be increased when it is combined with Methotrexate. |
Levorphanol | Levorphanol The risk or severity of CNS depression can be increased when Haloperidol is combined with Levorphanol. |
Primidone | Primidone The risk or severity of CNS depression can be increased when Haloperidol is combined with Primidone. |
Methsuximide | Methsuximide The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Methsuximide. |
Diethylpropion | Diethylpropion The therapeutic efficacy of Diethylpropion can be decreased when used in combination with Haloperidol. |
Chlorpromazine | Chlorpromazine The risk or severity of QTc prolongation can be increased when Chlorpromazine is combined with Haloperidol. |
Diazepam | Diazepam The risk or severity of CNS depression can be increased when Haloperidol is combined with Diazepam. |
Oxazepam | Oxazepam The risk or severity of CNS depression can be increased when Haloperidol is combined with Oxazepam. |
Flurazepam | Flurazepam The risk or severity of CNS depression can be increased when Haloperidol is combined with Flurazepam. |
Clorazepate | Clorazepate The risk or severity of CNS depression can be increased when Haloperidol is combined with Clorazepic acid. |
Lorazepam | Lorazepam The risk or severity of CNS depression can be increased when Lorazepam is combined with Haloperidol. |
Carmustine | Carmustine The metabolism of Haloperidol can be decreased when combined with Carmustine. |
Amantadine | Amantadine The risk or severity of QTc prolongation can be increased when Amantadine is combined with Haloperidol. |
Codeine | Codeine The risk or severity of CNS depression can be increased when Haloperidol is combined with Codeine. |
Meprobamate | Meprobamate The risk or severity of CNS depression can be increased when Meprobamate is combined with Haloperidol. |
Chlordiazepoxide | Chlordiazepoxide The risk or severity of CNS depression can be increased when Chlordiazepoxide is combined with Haloperidol. |
Bromocriptine | Bromocriptine The risk or severity of CNS depression can be increased when Haloperidol is combined with Bromocriptine. |
Tranylcypromine | Tranylcypromine The risk or severity of CNS depression can be increased when Haloperidol is combined with Tranylcypromine. |
Phenelzine | Phenelzine The risk or severity of CNS depression can be increased when Haloperidol is combined with Phenelzine. |
Procarbazine | Procarbazine The risk or severity of CNS depression can be increased when Procarbazine is combined with Haloperidol. |
Ergoloid Mesylates | Ergoloid Mesylates The risk or severity of CNS depression can be increased when Ergoloid mesylate is combined with Haloperidol. |
Tetracycline | Tetracycline The serum concentration of Tetracycline can be increased when it is combined with Haloperidol. |
Minocycline | Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Haloperidol. |
Prochlorperazine | Prochlorperazine The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Haloperidol. |
Thioridazine | Thioridazine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Thioridazine. |
Trifluoperazine | Trifluoperazine The risk or severity of CNS depression can be increased when Haloperidol is combined with Trifluoperazine. |
Bleomycin | Bleomycin Bleomycin may decrease the excretion rate of Haloperidol which could result in a higher serum level. |
Dapsone | Dapsone The serum concentration of Haloperidol can be increased when it is combined with Dapsone. |
Sulfadiazine | Sulfadiazine The serum concentration of Sulfadiazine can be increased when it is combined with Haloperidol. |
Oxycodone | Oxycodone The risk or severity of CNS depression can be increased when Oxycodone is combined with Haloperidol. |
Methadone | Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Haloperidol. |
Oxybutynin | Oxybutynin The serum concentration of Oxybutynin can be increased when it is combined with Haloperidol. |
Benztropine | Benztropine The risk or severity of adverse effects can be increased when Haloperidol is combined with Benzatropine. |
Maprotiline | Maprotiline The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Maprotiline. |
Ibuprofen | Ibuprofen The serum concentration of Haloperidol can be increased when it is combined with Ibuprofen. |
Trihexyphenidyl | Trihexyphenidyl The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Haloperidol. |
Orphenadrine | Orphenadrine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Orphenadrine. |
Perphenazine | Perphenazine The risk or severity of CNS depression can be increased when Haloperidol is combined with Perphenazine. |
Azathioprine | Azathioprine The metabolism of Azathioprine can be decreased when combined with Haloperidol. |
Fluphenazine | Fluphenazine The risk or severity of CNS depression can be increased when Haloperidol is combined with Fluphenazine. |
Phentermine | Phentermine The therapeutic efficacy of Phentermine can be decreased when used in combination with Haloperidol. |
Methylphenidate | Methylphenidate The risk or severity of adverse effects can be increased when Haloperidol is combined with Methylphenidate. |
Amoxapine | Amoxapine The serum concentration of Amoxapine can be increased when it is combined with Haloperidol. |
Sulfasalazine | Sulfasalazine The therapeutic efficacy of Haloperidol can be increased when used in combination with Sulfasalazine. |
Hydrocortisone | Hydrocortisone The serum concentration of Hydrocortisone can be increased when it is combined with Haloperidol. |
Doxorubicin | Doxorubicin The serum concentration of Haloperidol can be increased when it is combined with Doxorubicin. |
Phenazopyridine | Phenazopyridine Phenazopyridine may decrease the excretion rate of Haloperidol which could result in a higher serum level. |
Carbamazepine | Carbamazepine The metabolism of Carbamazepine can be increased when combined with Haloperidol. |
Molindone | Molindone The risk or severity of CNS depression can be increased when Haloperidol is combined with Molindone. |
Methyldopa | Methyldopa Haloperidol may decrease the excretion rate of Methyldopa which could result in a higher serum level. |
Clonidine | Clonidine The risk or severity of sedation can be increased when Clonidine is combined with Haloperidol. |
Hydralazine | Hydralazine The serum concentration of Hydralazine can be increased when it is combined with Haloperidol. |
Cimetidine | Cimetidine The serum concentration of Haloperidol can be increased when it is combined with Cimetidine. |
Gentamicin Injection | Gentamicin Injection Gentamicin may decrease the excretion rate of Haloperidol which could result in a higher serum level. |
Warfarin | Warfarin The serum concentration of Warfarin can be increased when it is combined with Haloperidol. |
Clonazepam | Clonazepam The risk or severity of CNS depression can be increased when Haloperidol is combined with Clonazepam. |
Loperamide | Loperamide The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Loperamide. |
Promethazine | Promethazine The risk or severity of QTc prolongation can be increased when Promethazine is combined with Haloperidol. |
Meclofenamate | Meclofenamate The therapeutic efficacy of Haloperidol can be increased when used in combination with Meclofenamic acid. |
Daunorubicin | Daunorubicin The serum concentration of Haloperidol can be increased when it is combined with Daunorubicin. |
Nitrofurantoin | Nitrofurantoin Haloperidol may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level. |
Griseofulvin | Griseofulvin The metabolism of Haloperidol can be increased when combined with Griseofulvin. |
Digoxin | Digoxin The risk or severity of QTc prolongation can be increased when Digoxin is combined with Haloperidol. |
Loxapine | Loxapine The risk or severity of CNS depression can be increased when Loxapine is combined with Haloperidol. |
Chloroquine | Chloroquine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Chloroquine. |
Quinine | Quinine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Quinine. |
Ethosuximide | Ethosuximide The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Haloperidol. |
Calcitriol | Calcitriol The serum concentration of Haloperidol can be increased when it is combined with Calcitriol. |
Triamterene | Triamterene The metabolism of Haloperidol can be decreased when combined with Triamterene. |
Sulfinpyrazone | Sulfinpyrazone The serum concentration of Haloperidol can be increased when it is combined with Sulfinpyrazone. |
Chlorothiazide | Chlorothiazide Chlorothiazide may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy. |
Chlorthalidone | Chlorthalidone Chlorthalidone may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy. |
Metolazone | Metolazone Haloperidol may increase the excretion rate of Metolazone which could result in a lower serum level and potentially a reduction in efficacy. |
Isosorbide | Isosorbide Isosorbide may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy. |
Clindamycin Injection | Clindamycin Injection The serum concentration of Clindamycin can be increased when it is combined with Haloperidol. |
Secobarbital | Secobarbital The risk or severity of CNS depression can be increased when Secobarbital is combined with Haloperidol. |
Desipramine | Desipramine The serum concentration of Desipramine can be increased when it is combined with Haloperidol. |
Amitriptyline | Amitriptyline The serum concentration of Haloperidol can be increased when it is combined with Amitriptyline. |
Imipramine | Imipramine The serum concentration of Haloperidol can be increased when it is combined with Imipramine. |
Probenecid | Probenecid The metabolism of Probenecid can be decreased when combined with Haloperidol. |
Quinidine | Quinidine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Quinidine. |
Procainamide | Procainamide The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Procainamide. |
Isoniazid | Isoniazid The serum concentration of Isoniazid can be increased when it is combined with Haloperidol. |
Pyrazinamide | Pyrazinamide Pyrazinamide may decrease the excretion rate of Haloperidol which could result in a higher serum level. |
Rifampin | Rifampin The metabolism of Haloperidol can be increased when combined with Rifampicin. |
Disopyramide | Disopyramide The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Disopyramide. |
Valproic Acid | Valproic Acid The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Haloperidol. |
Tamoxifen | Tamoxifen The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Haloperidol. |
Butabarbital | Butabarbital The risk or severity of CNS depression can be increased when Butabarbital is combined with Haloperidol. |
Liothyronine | Liothyronine Liothyronine may decrease the excretion rate of Haloperidol which could result in a higher serum level. |
Methimazole | Methimazole The serum concentration of Haloperidol can be increased when it is combined with Methimazole. |
Chlorpropamide | Chlorpropamide The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Haloperidol. |
Tolbutamide | Tolbutamide The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Haloperidol. |
Tolazamide | Tolazamide The therapeutic efficacy of Tolazamide can be decreased when used in combination with Haloperidol. |
Dextromethorphan | Dextromethorphan The risk or severity of CNS depression can be increased when Dextromethorphan is combined with Haloperidol. |
Cyclobenzaprine | Cyclobenzaprine The risk or severity of CNS depression can be increased when Haloperidol is combined with Cyclobenzaprine. |
Niacin | Niacin The serum concentration of Haloperidol can be increased when it is combined with Niacin. |
Baclofen | Baclofen The risk or severity of CNS depression can be increased when Baclofen is combined with Haloperidol. |
Doxylamine | Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Haloperidol. |
Cyproheptadine | Cyproheptadine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Cyproheptadine. |
Clemastine | Clemastine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Clemastine. |
Chlorpheniramine | Chlorpheniramine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Chlorpheniramine. |
Brompheniramine | Brompheniramine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Haloperidol. |
Meclizine | Meclizine The risk or severity of CNS depression can be increased when Haloperidol is combined with Meclizine. |
Ethambutol | Ethambutol Ethambutol may decrease the excretion rate of Haloperidol which could result in a higher serum level. |
Methyclothiazide | Methyclothiazide Methyclothiazide may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy. |
Hydrochlorothiazide | Hydrochlorothiazide The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Haloperidol. |
Dantrolene | Dantrolene The risk or severity of CNS depression can be increased when Haloperidol is combined with Dantrolene. |
Chlorzoxazone | Chlorzoxazone The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with Haloperidol. |
Carisoprodol | Carisoprodol The risk or severity of adverse effects can be increased when Carisoprodol is combined with Haloperidol. |
Methocarbamol | Methocarbamol The risk or severity of CNS depression can be increased when Methocarbamol is combined with Haloperidol. |
Pyridoxine | Pyridoxine Pyridoxine may decrease the excretion rate of Haloperidol which could result in a higher serum level. |
Folic Acid | Folic Acid Folic acid may decrease the excretion rate of Haloperidol which could result in a higher serum level. |
Danazol | Danazol The serum concentration of Haloperidol can be increased when it is combined with Danazol. |
Disulfiram | Disulfiram The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Haloperidol. |
Propranolol (Cardiovascular) | Propranolol (Cardiovascular) The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Propranolol. |
Pseudoephedrine | Pseudoephedrine The therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Haloperidol. |
Nortriptyline | Nortriptyline The serum concentration of Nortriptyline can be increased when it is combined with Haloperidol. |
Spironolactone | Spironolactone Spironolactone may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy. |
Amphotericin B Injection | Amphotericin B Injection The serum concentration of Haloperidol can be increased when it is combined with Amphotericin B. |
Phytonadione | Phytonadione Haloperidol may decrease the excretion rate of Phylloquinone which could result in a higher serum level. |
Amikacin Injection | Amikacin Injection Amikacin may decrease the excretion rate of Haloperidol which could result in a higher serum level. |
Nadolol | Nadolol The serum concentration of Nadolol can be increased when it is combined with Haloperidol. |
Butorphanol Injection | Butorphanol Injection The risk or severity of CNS depression can be increased when Haloperidol is combined with Butorphanol. |
Nalbuphine Injection | Nalbuphine Injection The risk or severity of CNS depression can be increased when Haloperidol is combined with Nalbuphine. |
Allopurinol | Allopurinol Allopurinol may decrease the excretion rate of Haloperidol which could result in a higher serum level. |
Oxytocin Injection | Oxytocin Injection The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Haloperidol. |
Trimethobenzamide | Trimethobenzamide The risk or severity of CNS depression can be increased when Haloperidol is combined with Trimethobenzamide. |
Flavoxate | Flavoxate Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Flavoxate. |
Papaverine | Papaverine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Papaverine. |
Fluorouracil Injection | Fluorouracil Injection The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Fluorouracil. |
Colchicine | Colchicine The metabolism of Colchicine can be decreased when combined with Haloperidol. |
Cefaclor | Cefaclor Cefaclor may decrease the excretion rate of Haloperidol which could result in a higher serum level. |
Cefadroxil | Cefadroxil Cefadroxil may decrease the excretion rate of Haloperidol which could result in a higher serum level. |
Cefazolin Injection | Cefazolin Injection Cefazolin may decrease the excretion rate of Haloperidol which could result in a higher serum level. |
Cephalexin | Cephalexin The serum concentration of Haloperidol can be increased when it is combined with Cephalexin. |
Cefoxitin Injection | Cefoxitin Injection Cefoxitin may decrease the excretion rate of Haloperidol which could result in a higher serum level. |
Dacarbazine | Dacarbazine The metabolism of Dacarbazine can be decreased when combined with Haloperidol. |
Acetazolamide | Acetazolamide The risk or severity of CNS depression can be increased when Haloperidol is combined with Acetazolamide. |
Cefotaxime Injection | Cefotaxime Injection Cefotaxime may decrease the excretion rate of Haloperidol which could result in a higher serum level. |
Calcitonin Salmon Injection | Calcitonin Salmon Injection Salmon calcitonin may decrease the excretion rate of Haloperidol which could result in a higher serum level. |
Ketoconazole | Ketoconazole The metabolism of Haloperidol can be decreased when combined with Ketoconazole. |
Pyrantel | Pyrantel The risk or severity of CNS depression can be increased when Haloperidol is combined with Pyrantel. |
Thiotepa Injection | Thiotepa Injection The serum concentration of Haloperidol can be increased when it is combined with Thiotepa. |
Vincristine Injection | Vincristine Injection The serum concentration of Vincristine can be increased when it is combined with Haloperidol. |
Vinblastine | Vinblastine The serum concentration of Haloperidol can be increased when it is combined with Vinblastine. |
Ethacrynic Acid | Ethacrynic Acid Etacrynic acid may decrease the excretion rate of Haloperidol which could result in a higher serum level. |
Colistimethate Injection | Colistimethate Injection Colistimethate may decrease the excretion rate of Haloperidol which could result in a higher serum level. |
Metoprolol | Metoprolol The serum concentration of Haloperidol can be increased when it is combined with Metoprolol. |
Hydroxyzine | Hydroxyzine The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Haloperidol. |
Thiothixene | Thiothixene The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Thiothixene. |
Aspirin | Aspirin The therapeutic efficacy of Haloperidol can be increased when used in combination with Acetylsalicylic acid. |
Salsalate | Salsalate The therapeutic efficacy of Haloperidol can be increased when used in combination with Salsalate. |
Alprazolam | Alprazolam The metabolism of Alprazolam can be decreased when combined with Haloperidol. |
Temazepam | Temazepam The risk or severity of CNS depression can be increased when Temazepam is combined with Haloperidol. |
Triazolam | Triazolam The risk or severity of CNS depression can be increased when Haloperidol is combined with Triazolam. |
Dicyclomine | Dicyclomine Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine. |
Hyoscyamine | Hyoscyamine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Haloperidol. |
Propantheline | Propantheline Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Propantheline. |
Trimethoprim | Trimethoprim The serum concentration of Haloperidol can be increased when it is combined with Trimethoprim. |
Diltiazem | Diltiazem The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Haloperidol. |
Nifedipine | Nifedipine The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Haloperidol. |
Timolol | Timolol The risk or severity of QTc prolongation can be increased when Timolol is combined with Haloperidol. |
Verapamil | Verapamil The serum concentration of Haloperidol can be increased when it is combined with Verapamil. |
Atenolol | Atenolol The serum concentration of Atenolol can be increased when it is combined with Haloperidol. |
Pindolol | Pindolol The risk or severity of CNS depression can be increased when Haloperidol is combined with Pindolol. |
Cisplatin Injection | Cisplatin Injection Haloperidol may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
Diflunisal | Diflunisal The therapeutic efficacy of Haloperidol can be increased when used in combination with Diflunisal. |
Piroxicam | Piroxicam The therapeutic efficacy of Haloperidol can be increased when used in combination with Piroxicam. |
Bumetanide | Bumetanide Haloperidol may increase the excretion rate of Bumetanide which could result in a lower serum level and potentially a reduction in efficacy. |
Streptozocin | Streptozocin The metabolism of Haloperidol can be increased when combined with Streptozocin. |
Etoposide | Etoposide The serum concentration of Etoposide can be increased when it is combined with Haloperidol. |
Glyburide | Glyburide The serum concentration of Haloperidol can be increased when it is combined with Glyburide. |
Glipizide | Glipizide The therapeutic efficacy of Glipizide can be decreased when used in combination with Haloperidol. |
Indapamide | Indapamide The risk or severity of QTc prolongation can be increased when Indapamide is combined with Haloperidol. |
Amoxicillin | Amoxicillin Haloperidol may decrease the excretion rate of Amoxicillin which could result in a higher serum level. |
Nafcillin Injection | Nafcillin Injection The metabolism of Haloperidol can be increased when combined with Nafcillin. |
Oxacillin Injection | Oxacillin Injection Haloperidol may decrease the excretion rate of Oxacillin which could result in a higher serum level. |
Pentoxifylline | Pentoxifylline The metabolism of Pentoxifylline can be decreased when combined with Haloperidol. |
Pentamidine Injection | Pentamidine Injection The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Pentamidine. |
Ceftriaxone Injection | Ceftriaxone Injection Ceftriaxone may decrease the excretion rate of Haloperidol which could result in a higher serum level. |
Labetalol | Labetalol The serum concentration of Haloperidol can be increased when it is combined with Labetalol. |
Auranofin | Auranofin Haloperidol may decrease the excretion rate of Auranofin which could result in a higher serum level. |
Leuprolide Injection | Leuprolide Injection The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Haloperidol. |
Gemfibrozil | Gemfibrozil The serum concentration of Haloperidol can be increased when it is combined with Gemfibrozil. |
Guanabenz | Guanabenz The metabolism of Guanabenz can be decreased when combined with Haloperidol. |
Dipivefrin Ophthalmic | Dipivefrin Ophthalmic Adefovir dipivoxil may decrease the excretion rate of Haloperidol which could result in a higher serum level. |
Ceftazidime Injection | Ceftazidime Injection Ceftazidime may decrease the excretion rate of Haloperidol which could result in a higher serum level. |
Ketoprofen | Ketoprofen The therapeutic efficacy of Haloperidol can be increased when used in combination with Ketoprofen. |
Cefotetan Injection | Cefotetan Injection Cefotetan may decrease the excretion rate of Haloperidol which could result in a higher serum level. |
Pimozide | Pimozide The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Pimozide. |
Flurbiprofen | Flurbiprofen The therapeutic efficacy of Haloperidol can be increased when used in combination with Flurbiprofen. |
Amiodarone | Amiodarone The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Amiodarone. |
Aztreonam Injection | Aztreonam Injection Aztreonam may decrease the excretion rate of Haloperidol which could result in a higher serum level. |
Buspirone | Buspirone The serum concentration of Buspirone can be increased when it is combined with Haloperidol. |
Lovastatin | Lovastatin The metabolism of Lovastatin can be decreased when combined with Haloperidol. |
Ciprofloxacin | Ciprofloxacin The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Haloperidol. |
Mesalamine | Mesalamine The therapeutic efficacy of Haloperidol can be increased when used in combination with Mesalazine. |
Diclofenac | Diclofenac The serum concentration of Haloperidol can be increased when it is combined with Diclofenac. |
Fluoxetine | Fluoxetine The metabolism of Haloperidol can be decreased when combined with Fluoxetine. |
Nimodipine | Nimodipine The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Haloperidol. |
Interferon Alfa-2b Injection | Interferon Alfa-2b Injection The metabolism of Haloperidol can be decreased when combined with Interferon alfa-2b. |
Clozapine | Clozapine The risk or severity of QTc prolongation can be increased when Clozapine is combined with Haloperidol. |
Estazolam | Estazolam The risk or severity of CNS depression can be increased when Haloperidol is combined with Estazolam. |
Idarubicin | Idarubicin The serum concentration of Idarubicin can be increased when it is combined with Haloperidol. |
Ofloxacin | Ofloxacin The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Ofloxacin. |
Didanosine | Didanosine Haloperidol may decrease the excretion rate of Didanosine which could result in a higher serum level. |
Pentostatin Injection | Pentostatin Injection Haloperidol may decrease the excretion rate of Pentostatin which could result in a higher serum level. |
Clarithromycin | Clarithromycin The risk or severity of QTc prolongation can be increased when Clarithromycin is combined with Haloperidol. |
Etodolac | Etodolac The therapeutic efficacy of Haloperidol can be increased when used in combination with Etodolac. |
Felodipine | Felodipine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Felodipine. |
Fosinopril | Fosinopril Fosinopril may decrease the excretion rate of Haloperidol which could result in a higher serum level. |
Nabumetone | Nabumetone The therapeutic efficacy of Haloperidol can be increased when used in combination with Nabumetone. |
Simvastatin | Simvastatin The serum concentration of Simvastatin can be increased when it is combined with Haloperidol. |
Amlodipine | Amlodipine The risk or severity of QTc prolongation can be increased when Amlodipine is combined with Haloperidol. |
Teniposide Injection | Teniposide Injection The serum concentration of Haloperidol can be increased when it is combined with Teniposide. |
Itraconazole | Itraconazole The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Haloperidol. |
Lisinopril | Lisinopril Haloperidol may decrease the excretion rate of Lisinopril which could result in a higher serum level. |
Oxaprozin | Oxaprozin The therapeutic efficacy of Haloperidol can be increased when used in combination with Oxaprozin. |
Atovaquone | Atovaquone The serum concentration of Haloperidol can be increased when it is combined with Atovaquone. |
Rifabutin | Rifabutin The serum concentration of Haloperidol can be increased when it is combined with Rifabutin. |
Sotalol | Sotalol The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Sotalol. |
Bisoprolol | Bisoprolol The serum concentration of Bisoprolol can be increased when it is combined with Haloperidol. |
Zolpidem | Zolpidem Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
Doxazosin | Doxazosin The serum concentration of Doxazosin can be increased when it is combined with Haloperidol. |
Isradipine | Isradipine The risk or severity of QTc prolongation can be increased when Isradipine is combined with Haloperidol. |
Omeprazole | Omeprazole The serum concentration of Haloperidol can be increased when it is combined with Omeprazole. |
Cisapride | Cisapride The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Cisapride. |
Gabapentin | Gabapentin The risk or severity of CNS depression can be increased when Haloperidol is combined with Gabapentin. |
Fluvastatin | Fluvastatin The serum concentration of Fluvastatin can be increased when it is combined with Haloperidol. |
Venlafaxine | Venlafaxine The serum concentration of Haloperidol can be increased when it is combined with Venlafaxine. |
Stavudine | Stavudine Haloperidol may increase the neurotoxic activities of Stavudine. |
Famciclovir | Famciclovir The serum concentration of Famciclovir can be increased when it is combined with Haloperidol. |
Fluvoxamine | Fluvoxamine The risk or severity of CNS depression can be increased when Fluvoxamine is combined with Haloperidol. |
Nefazodone | Nefazodone The risk or severity of CNS depression can be increased when Haloperidol is combined with Nefazodone. |
Lamotrigine | Lamotrigine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Lamotrigine. |
Losartan | Losartan The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Losartan. |
Valacyclovir | Valacyclovir Valaciclovir may decrease the excretion rate of Haloperidol which could result in a higher serum level. |
Tramadol | Tramadol The metabolism of Haloperidol can be decreased when combined with Tramadol. |
Vinorelbine Injection | Vinorelbine Injection The serum concentration of Haloperidol can be increased when it is combined with Vinorelbine. |
Carboplatin Injection | Carboplatin Injection Carboplatin may decrease the excretion rate of Haloperidol which could result in a higher serum level. |
Moexipril | Moexipril The risk or severity of QTc prolongation can be increased when Moexipril is combined with Haloperidol. |
Lansoprazole | Lansoprazole The serum concentration of Haloperidol can be increased when it is combined with Lansoprazole. |
Ifosfamide Injection | Ifosfamide Injection The serum concentration of Ifosfamide can be increased when it is combined with Haloperidol. |
Nicardipine | Nicardipine The risk or severity of QTc prolongation can be increased when Nicardipine is combined with Haloperidol. |
Bupropion | Bupropion The risk or severity of seizure can be increased when Haloperidol is combined with Bupropion. |
Ticlopidine | Ticlopidine The serum concentration of Haloperidol can be increased when it is combined with Ticlopidine. |
Saquinavir | Saquinavir The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Saquinavir. |
Metformin | Metformin The therapeutic efficacy of Metformin can be decreased when used in combination with Haloperidol. |
Nisoldipine | Nisoldipine The serum concentration of Nisoldipine can be increased when it is combined with Haloperidol. |
Lamivudine | Lamivudine Haloperidol may decrease the excretion rate of Lamivudine which could result in a higher serum level. |
Riluzole | Riluzole The risk or severity of CNS depression can be increased when Haloperidol is combined with Riluzole. |
Acarbose | Acarbose The therapeutic efficacy of Acarbose can be decreased when used in combination with Haloperidol. |
Glimepiride | Glimepiride The therapeutic efficacy of Glimepiride can be decreased when used in combination with Haloperidol. |
Gemcitabine Injection | Gemcitabine Injection Gemcitabine may decrease the excretion rate of Haloperidol which could result in a higher serum level. |
Indinavir | Indinavir The serum concentration of Indinavir can be increased when it is combined with Haloperidol. |
Ritonavir | Ritonavir The serum concentration of Haloperidol can be increased when it is combined with Ritonavir. |
Docetaxel Injection | Docetaxel Injection The serum concentration of Docetaxel can be increased when it is combined with Haloperidol. |
Cidofovir Injection | Cidofovir Injection Cidofovir may decrease the excretion rate of Haloperidol which could result in a higher serum level. |
Meropenem Injection | Meropenem Injection Haloperidol may decrease the excretion rate of Meropenem which could result in a higher serum level. |
Clomipramine | Clomipramine The serum concentration of Clomipramine can be increased when it is combined with Haloperidol. |
Zafirlukast | Zafirlukast The serum concentration of Haloperidol can be increased when it is combined with Zafirlukast. |
Fosfomycin | Fosfomycin Haloperidol may decrease the excretion rate of Fosfomycin which could result in a higher serum level. |
Mirtazapine | Mirtazapine The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Haloperidol. |
Topiramate | Topiramate The risk or severity of CNS depression can be increased when Topiramate is combined with Haloperidol. |
Zileuton | Zileuton The serum concentration of Zileuton can be increased when it is combined with Haloperidol. |
Valsartan | Valsartan The metabolism of Haloperidol can be decreased when combined with Valsartan. |
Insulin Lispro Injection | Insulin Lispro Injection The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Haloperidol. |
Pramipexole | Pramipexole The therapeutic efficacy of Pramipexole can be decreased when used in combination with Haloperidol. |
Donepezil | Donepezil The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Donepezil. |
Nelfinavir | Nelfinavir The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Haloperidol. |
Azithromycin | Azithromycin The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Haloperidol. |
Loratadine | Loratadine The risk or severity of QTc prolongation can be increased when Loratadine is combined with Haloperidol. |
Carvedilol | Carvedilol The serum concentration of Carvedilol can be increased when it is combined with Haloperidol. |
Nilutamide | Nilutamide The metabolism of Haloperidol can be decreased when combined with Nilutamide. |
Flutamide | Flutamide The serum concentration of Haloperidol can be increased when it is combined with Flutamide. |
Selegiline | Selegiline The risk or severity of CNS depression can be increased when Haloperidol is combined with Selegiline. |
Bicalutamide | Bicalutamide The serum concentration of Haloperidol can be increased when it is combined with Bicalutamide. |
Sertraline | Sertraline The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Sertraline. |
Propafenone | Propafenone The risk or severity of QTc prolongation can be increased when Propafenone is combined with Haloperidol. |
Letrozole | Letrozole The serum concentration of Haloperidol can be increased when it is combined with Letrozole. |
Raloxifene | Raloxifene The serum concentration of Haloperidol can be increased when it is combined with Raloxifene. |
Irbesartan | Irbesartan The serum concentration of Irbesartan can be increased when it is combined with Haloperidol. |
Tamsulosin | Tamsulosin The serum concentration of Tamsulosin can be increased when it is combined with Haloperidol. |
Ropinirole | Ropinirole The therapeutic efficacy of Ropinirole can be decreased when used in combination with Haloperidol. |
Finasteride | Finasteride The serum concentration of Finasteride can be increased when it is combined with Haloperidol. |
Quetiapine | Quetiapine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Quetiapine. |
Cefepime Injection | Cefepime Injection Cefepime may decrease the excretion rate of Haloperidol which could result in a higher serum level. |
Cefprozil | Cefprozil Cefprozil may decrease the excretion rate of Haloperidol which could result in a higher serum level. |
Cefpodoxime | Cefpodoxime Cefpodoxime may decrease the excretion rate of Haloperidol which could result in a higher serum level. |
Cetirizine | Cetirizine The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Haloperidol. |
Paroxetine | Paroxetine The risk or severity of CNS depression can be increased when Haloperidol is combined with Paroxetine. |
Tolcapone | Tolcapone The risk or severity of CNS depression can be increased when Tolcapone is combined with Haloperidol. |
Citalopram | Citalopram The risk or severity of QTc prolongation can be increased when Citalopram is combined with Haloperidol. |
Capecitabine | Capecitabine The metabolism of Haloperidol can be decreased when combined with Capecitabine. |
Efavirenz | Efavirenz The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Haloperidol. |
Abacavir | Abacavir Haloperidol may decrease the excretion rate of Abacavir which could result in a higher serum level. |
Sildenafil | Sildenafil The serum concentration of Haloperidol can be increased when it is combined with Sildenafil. |
Pioglitazone | Pioglitazone The serum concentration of Pioglitazone can be increased when it is combined with Haloperidol. |
Celecoxib | Celecoxib The serum concentration of Haloperidol can be increased when it is combined with Celecoxib. |
Rosiglitazone | Rosiglitazone The serum concentration of Rosiglitazone can be increased when it is combined with Haloperidol. |
Tolterodine | Tolterodine The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Haloperidol. |
Thalidomide | Thalidomide Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
Oseltamivir | Oseltamivir Oseltamivir may decrease the excretion rate of Haloperidol which could result in a higher serum level. |
Balsalazide | Balsalazide The therapeutic efficacy of Haloperidol can be increased when used in combination with Balsalazide. |
Nateglinide | Nateglinide The serum concentration of Nateglinide can be increased when it is combined with Haloperidol. |
Galantamine | Galantamine The risk or severity of QTc prolongation can be increased when Galantamine is combined with Haloperidol. |
Levetiracetam | Levetiracetam The risk or severity of CNS depression can be increased when Haloperidol is combined with Levetiracetam. |
Rabeprazole | Rabeprazole The serum concentration of Rabeprazole can be increased when it is combined with Haloperidol. |
Terbinafine | Terbinafine The serum concentration of Haloperidol can be increased when it is combined with Terbinafine. |
Content provided by: AHFS® Patient Medication Information™. © Copyright, 2021. The American Society of Health-System Pharmacists